-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brincidofovir in Adenoviridae Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brincidofovir in Adenoviridae Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brincidofovir in Adenoviridae Infections Drug Details: Brincidofovir (Tembexa) is an alkoxyalkyl ester...
-
Product Insights
Polyomavirus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Polyomavirus Infections - Drugs In Development, 2023’, provides an overview of the Polyomavirus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Polyomavirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Lymphoblastic Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Lymphoblastic Lymphoma - Drugs In Development, 2023’, provides an overview of the Lymphoblastic Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lymphoblastic Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Nodal Marginal Zone B-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Nodal Marginal Zone B-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Nodal Marginal Zone B-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nodal Marginal Zone B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Splenic Marginal Zone B-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Splenic Marginal Zone B-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Splenic Marginal Zone B-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Splenic Marginal Zone B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Simplexvirus (HSV) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Simplexvirus (HSV) Infections - Drugs In Development, 2023’, provides an overview of the Simplexvirus (HSV) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Simplexvirus (HSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Lymphocryptovirus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Lymphocryptovirus Infections - Drugs In Development, 2023’, provides an overview of the Lymphocryptovirus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lymphocryptovirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) - Drugs In Development, 2023’, provides an overview of the Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers...
-
Product Insights
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) - Drugs In Development, 2023’, provides an overview of the Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...